Nkarta Inc (NAS:NKTX)
$ 2.87 -0.12 (-4.01%) Market Cap: 202.53 Mil Enterprise Value: 4.93 Mil PE Ratio: 0 PB Ratio: 0.47 GF Score: 38/100

Nkarta Inc at Stifel Healthcare Conference Transcript

Nov 14, 2023 / 03:55PM GMT
Release Date Price: $2.3 (+20.42%)
Stephen Willey
Stifel Healthcare Conference - Moderator

Let's get started. I'm Stephen Willey, one of the senior biotech analysts here at Stifel. and glad to have with us from Nkarta CEO, Paul Hastings; and Chief Medical Officer, David Shook; maybe before we jump into Q&A, can you just kind of provide a quick background, an update on the Nkarta story?

Paul Hastings
Nkarta, Inc. - CEO

Yes. So we are a cell therapy CAR-NK company. We have two clinical programs. One is NKX101, which is an NKG2D directed CAR-NK for AML patients and which is in the middle of a Phase 1/2 study and the second one is NKX019, which is a CAR-NK CD19 program, which is in NHL as well as now in lupus nephritis, we have INDs for all those things we're looking at compressed dose. Those, mark, we're looking at compressed dosing in NHL and which David will get into a little bit later.

I expect Steve will be asking a lot of lupus questions all first and where we just had an IND. accepted for lupus nephritis and we intend to expand into other indications in autoimmune disease. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot